Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company operating a growing contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement expands an existing customer relationship and includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. For investors, this development is significant because it validates Scinai's strategic pivot toward contract manufacturing as a near-term revenue driver while its therapeutic pipeline continues to mature.
The engagement covers development and clinical manufacturing services for an investigational oncology product, with revenue expected during 2026 and 2027 and stability services extending beyond 2027. Following the agreement, Scinai's committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. This sharp increase in committed orders underscores the company's ability to convert its CDMO capabilities into tangible commercial traction, a critical milestone for a small-cap biopharma seeking to diversify revenue streams and reduce reliance on clinical-stage milestones.
The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. If realized, these opportunities would extend the revenue runway well into the latter part of the decade, providing a more predictable financial foundation. To view the full press release, visit https://ibn.fm/5jaNp. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The dual-pronged strategy allows Scinai to leverage its manufacturing infrastructure for near-term revenue while continuing to develop its immunology assets.
MissionIR, a specialized communications platform, distributes news and updates for Scinai Immunotherapeutics and other companies. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides a range of services including InvestorWire for wire distribution, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit MissionIR and review the full terms at https://www.MissionIR.com/Disclaimer.
